You are here: Industry Insights > Rigel

News List

Rigel Pharmaceuticals Provides Update on COVID-19 Program prnewswire
August 16, 2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that clinical data submitted in late-May from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib.
Rigel concludes subject enrolment in NIH-sponsored Covid-19 trial pharmaceutical-technology
March 15, 2021
Rigel Pharmaceuticals has concluded patient enrolment in a Phase II clinical trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, for treating hospitalised Covid-19 patients.
Eli Lilly enters into $960 million deal with Rigel Pharma to develop autoimmune therapy expresspharma
February 20, 2021
Under the deal, Lilly will foot the costs of global commercialisation for the therapy, R552, and Rigel will have the right to co-sell the treatment in the US.
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients prnewswire
February 01, 2021
Rigel Pharmaceuticals, Inc. announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel's ongoing Phase 3 ...
Rigel, Inova Enrolls First Patients in Fostamatinib Trial for Hospitalized COVID-19 Patients americanpharmaceuticalreview
October 16, 2020
Rigel Pharmaceuticals announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients.
Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients americanpharmaceuticalreview
September 27, 2020
Rigel Pharmaceuticals announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients.
Rigel Announces Trial of Fostamatinib for COVID-19 Pneumonia americanpharmaceuticalreview
July 22, 2020
Rigel Pharmaceuticals announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of COVID-19 ...
Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate americanpharmaceuticalreview
May 17, 2019
Rigel Pharmaceuticals has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm antibody autoimmune hemolytic anemia (AIHA).
Rigel & Kissei Enter Agreement contractpharma
October 30, 2018
Rigel & Kissei Enter Agreement
Rigel Receives EMA Validation for Fostamatinib americanpharmaceuticalreview
October 12, 2018
Rigel Pharmaceuticals announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for fostamatinib in adult chronic immune thrombocytopenia.

Previous page 1 2 Next page